Clearblue Study Finds More Than Half of Women Who Tried to Conceive in the Past Year Say Earlier Fertility Knowledge Would Have Changed When They Started a Family

Clearblue’s commissioned survey of 1,320 U.S. women ages 20–45 found that 55% of 311 women who had tried to conceive in the past year said earlier fertility knowledge would have changed when they started a family; 59% of that subgroup began researching fertility only after trying unsuccessfully. The study also found that 84% said formal sex education prepared them to prevent pregnancy, versus 41% who said it prepared them to identify their fertile window. Clearblue launched ClearblueU, an education platform covering menstruation, ovulation, conception and pregnancy; the survey reports respondents’ views and does not establish that earlier education would change pregnancy outcomes.

Analysis

Commercial signal, not a demonstrated demand inflection. ClearblueU could widen the funnel for Clearblue’s ovulation tests by engaging consumers before they are actively trying to conceive, then directing some toward paid physical products. The second-order beneficiaries may include fertility clinics and reproductive-health providers if better awareness leads to earlier consultations; conversely, improved cycle timing could reduce some avoidable months of trying. Net category impact is unclear. The education-to-product link also creates a credibility risk: the study was commissioned by Clearblue, reports self-assessments rather than changed behavior, and does not establish that education improves conception outcomes. The company’s own disclaimer that LH detection does not confirm ovulation limits how strongly the product can be positioned as a solution.

Near term, this is primarily a marketing and brand-engagement event; there is no disclosed uptake, revenue contribution, or independent evidence of incremental test sales. Over 1–3 months, monitor platform reach, retailer sell-through, and whether the phased content rollout converts into repeat purchases. Over 6–18 months, the more relevant question is whether Clearblue can build durable app engagement and category growth without encountering privacy, medical-claims, or trust issues. SPD Swiss Precision Diagnostics is a P&G–Abbott joint venture, but the article provides no economics to estimate parent-level earnings sensitivity. The contrarian read: the education gap may be real, but better awareness does not necessarily mean more demand for branded tests; consumers may instead use free apps, seek clinical advice, or make no change. No directional trade is justified on this release alone.

Key Decisions for Investors

• No event-driven position in Procter & Gamble or Abbott: the release provides no evidence of material incremental sales or a change in earnings outlook, and the Clearblue business contribution is not quantified.
• Add ClearblueU to a 1–3 month watchlist. Look for measurable audience engagement, conversion to ovulation-test purchases, and repeat use; treat views or email sign-ups alone as insufficient proof of commercial impact.
• Monitor competing fertility apps and home-test offerings for response. A stronger education funnel could expand category demand, but free digital substitutes may capture engagement without generating branded test sales.
• Falsification/watch items: weak platform engagement or no observable retail sell-through lift would undermine the funnel thesis; adverse scrutiny of health claims or reproductive-data handling could turn a low-cost brand initiative into a trust or compliance overhang.